P0068
Anti-p62/SQSTM1 (C-terminal) antibody produced in rabbit
affinity isolated antibody, buffered aqueous solution
Synonym(s):
Anti-Sequestosome 1, Anti-Ubiquitin-binding protein p62
Sign Into View Organizational & Contract Pricing
All Photos(2)
About This Item
UNSPSC Code:
12352203
NACRES:
NA.41
Recommended Products
biological source
rabbit
conjugate
unconjugated
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
form
buffered aqueous solution
mol wt
antigen ~62 kDa
species reactivity
rat, mouse, human
concentration
~1.0 mg/mL
technique(s)
immunoprecipitation (IP): 2-4 μg using whole extract of NIH-3T3 cells
western blot: 2-4 μg/mL using whole extracts of rat PC12 cells
western blot: 4-8 μg/mL using whole extracts of human A549 cells.
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
human ... SQSTM1(8878)
mouse ... Sqstm1(18412)
rat ... Sqstm1(113894)
Related Categories
General description
The p62 protein/sequestosome 1 (SQSTM1) comprises a Phox and Bem1p (PB1) domain at the NH2-terminal, a ZZ type zinc finger domain, a Pro, Glu, Ser, and Thr (PEST) region consisting of putative phosphorylation sites, and a ubiquitin-associated (UBA) domain at the COOH-terminal. The SQSTM1 gene is mapped to the human chromosome location 5q35.3.
Specificity
Anti-p62/SQSTM1 (C-terminal) recognizes human, rat, and mouse p62/SQSTM1.
Application
Rabbit polyclonal anti-SQSTM1 antibody has been used:
- in immunoblotting
- in immunoprecipitation
- as a probe to determine the presence and roles of p62 protein/sequestosome 1 in processes such as autophagy
Biochem/physiol Actions
The p62 protein/sequestosome 1 (SQSTM1) is a multifunctional protein, which binds to ubiquitin. It acts as a scaffold protein for the nuclear factor kappa-B (NF-ΚB) signaling pathway. SQSTM1 also regulates apoptosis and autophagy. Mutations in this gene lead to sporadic and familial Paget disease of bone. It is also associated with protein aggregation diseases, such as Lewy bodies in Parkinson′s disease, neurofibrillary tangles in Alzheimer′s disease, and huntingtin aggregates. SQSTM1 is commonly found in inclusion bodies containing polyubiquitinated protein aggregates that accumulate in several degenerative diseases. p62 polymerizes through its N-terminal Phox and Bem1p (PB1) domain and interacts with polyubiquitinated proteins through its C-terminal ubiquitin-associated (UBA) domain. p62 acts as a linker between protein aggregates and the autophagy machinery.
Physical form
Solution in 0.01 M phosphate buffered saline pH 7.4, containing 15 mM sodium azide.
Storage and Stability
For continuous use, store at 2–8 °C for up to one month. For extended storage freeze in working aliquots. Repeated freezing and thawing is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilution samples should be discarded if not used within 12 hours.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
recommended
Product No.
Description
Pricing
related product
Product No.
Description
Pricing
Storage Class Code
10 - Combustible liquids
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Personal Protective Equipment
dust mask type N95 (US), Eyeshields, Gloves
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Christine Knies et al.
ChemistryOpen, 5(2), 129-141 (2016-06-17)
We report on the synthesis of two series of canonical purine ß-d-ribonucleoside nucleolipids derived from inosine and adenosine, which have been characterized by elemental analyses, electrospray ionization mass spectrometry (ESI MS) as well as by (1)H and (13)C NMR, and pH-dependent
Stuart H Ralston et al.
Lancet (London, England), 372(9633), 155-163 (2008-07-16)
Paget's disease of bone is a common disease characterised by focal areas of increased bone turnover, affecting one or several bones throughout the skeleton. Paget's disease is often asymptomatic but can be associated with bone pain and other complications such
Geir Bjørkøy et al.
Autophagy, 2(2), 138-139 (2006-07-29)
In eukaryotic cells short-lived proteins are degraded in a specific process by the ubiquitin-proteasome system (UPS), whereas long-lived proteins and damaged organelles are degraded by macroautophagy (hereafter referred to as autophagy). A growing body of evidence now suggests that autophagy
Frédéric Gros et al.
Autophagy, 8(7), 1113-1123 (2012-04-24)
Macroautophagy was recently shown to regulate both lymphocyte biology and innate immunity. In this study we sought to determine whether a deregulation of autophagy was linked to the development of autoimmunity. Genome-wide association studies have pointed out nucleotide polymorphisms that
Gabriel Alejandro Bonaterra et al.
Toxicology reports, 1, 843-857 (2014-10-22)
During therapeutic interventions, blood concentrations of intravenously applied drugs are higher, and their onset of pharmacological action is faster than with other routes of drug administration. However, acute drug therapy often produces nephrotoxic side effects, as commonly seen after treatment
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service